ETF Holdings Breakdown of CTKB

News associated with CTKB

Quantinno Capital Management LP Purchases New Shares in Cytek Biosciences, Inc. (NASDAQ:CTKB)

Quantinno Capital Management LP bought a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 14,220 shares of the company’s stock, valued at approximately $92,000. Several other institutional investors have also modified […] - 2025-05-29 09:22:53

Millennium Management LLC Has $5.22 Million Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)

Millennium Management LLC increased its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 321.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 803,923 shares of the company’s stock after acquiring an additional 613,314 shares during the quarter. Millennium Management […] - 2025-05-29 08:20:53

Morgan Stanley Has Lowered Expectations for Cytek Biosciences (NASDAQ:CTKB) Stock Price

Cytek Biosciences (NASDAQ:CTKB – Free Report) had its price objective reduced by Morgan Stanley from $9.00 to $7.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the stock. Other equities research analysts have also recently issued research reports about the stock. TD Cowen cut shares of Cytek […] - 2025-05-29 06:00:47

Price T Rowe Associates Inc. MD Purchases 7,686 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)

Price T Rowe Associates Inc. MD lifted its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 19.5% in the 4th quarter, HoldingsChannel reports. The fund owned 47,189 shares of the company’s stock after purchasing an additional 7,686 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Cytek Biosciences […] - 2025-05-16 07:31:02

The Goldman Sachs Group Issues Pessimistic Forecast for Cytek Biosciences (NASDAQ:CTKB) Stock Price

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) had its price objective reduced by equities researchers at The Goldman Sachs Group from $3.50 to $3.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “sell” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 0.67% […] - 2025-05-14 07:48:57

Voya Investment Management LLC Sells 3,547 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)

Voya Investment Management LLC cut its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 8.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,749 shares of the company’s stock after selling 3,547 shares during the […] - 2025-05-13 08:54:58

Cytek Biosciences (NASDAQ:CTKB) Cut to “Hold” at TD Cowen

TD Cowen cut shares of Cytek Biosciences (NASDAQ:CTKB – Free Report) from a buy rating to a hold rating in a report issued on Friday morning, MarketBeat reports. They currently have $4.00 price objective on the stock. CTKB has been the subject of a number of other research reports. Piper Sandler lowered their target price […] - 2025-05-12 07:38:52

Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Purchased by Legal & General Group Plc

Legal & General Group Plc increased its position in Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 3.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 313,037 shares of the company’s stock after acquiring an additional 11,346 shares during the period. Legal […] - 2025-04-25 08:16:53

Renaissance Technologies LLC Purchases 251,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)

Renaissance Technologies LLC grew its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 118.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 462,600 shares of the company’s stock after purchasing an additional 251,000 shares during the quarter. Renaissance Technologies LLC owned about […] - 2025-04-24 07:50:56

ExodusPoint Capital Management LP Has $503,000 Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)

ExodusPoint Capital Management LP reduced its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 35.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,536 shares of the company’s stock after selling 41,706 shares during the quarter. ExodusPoint […] - 2025-04-13 08:29:02

Wellington Management Group LLP Has $9.85 Million Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)

Wellington Management Group LLP decreased its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 24.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,517,214 shares of the company’s stock after selling 489,925 shares during the […] - 2025-04-10 09:23:16

American Century Companies Inc. Raises Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)

American Century Companies Inc. boosted its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 10.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 204,745 shares of the company’s stock after buying an additional 19,802 shares during the period. American Century Companies Inc.’s holdings in Cytek […] - 2025-04-10 08:00:50

KLP Kapitalforvaltning AS Purchases Shares of 20,200 Cytek Biosciences, Inc. (NASDAQ:CTKB)

KLP Kapitalforvaltning AS acquired a new position in Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 20,200 shares of the company’s stock, valued at approximately $131,000. A number of other large investors have also […] - 2025-04-10 07:20:51

Prudential Financial Inc. Purchases 63,600 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)

Prudential Financial Inc. raised its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 57.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,382 shares of the company’s stock after acquiring an additional 63,600 shares during the period. […] - 2025-04-07 07:42:53

Cibc World Markets Corp Buys Shares of 11,358 Cytek Biosciences, Inc. (NASDAQ:CTKB)

Cibc World Markets Corp purchased a new position in Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 11,358 shares of the company’s stock, valued at approximately $74,000. Several other large investors also recently made […] - 2025-03-28 08:16:54

Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC boosted its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 114.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 49,704 shares of the company’s stock after buying an additional 26,567 shares during the quarter. Intech Investment […] - 2025-03-26 09:16:50

Cytek Biosciences (NASDAQ:CTKB) Earns “Overweight” Rating from Stephens

Cytek Biosciences (NASDAQ:CTKB – Get Free Report)‘s stock had its “overweight” rating restated by Stephens in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $6.00 price objective on the stock. Stephens’ target price points to a potential upside of 47.78% from the company’s current price. CTKB has been […] - 2025-03-21 06:42:53

Piper Sandler Issues Pessimistic Forecast for Cytek Biosciences (NASDAQ:CTKB) Stock Price

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) had its price objective cut by research analysts at Piper Sandler from $8.50 to $8.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price objective would indicate a potential upside of 78.97% from the stock’s current price. […] - 2025-03-06 07:27:22

Cytek Biosciences, Inc. (NASDAQ:CTKB) Stake Boosted by Principal Financial Group Inc.

Principal Financial Group Inc. increased its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 0.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 506,925 shares of the company’s stock after purchasing an additional 3,753 shares during the period. Principal Financial Group Inc.’s holdings in Cytek Biosciences were worth $3,290,000 as […] - 2025-03-05 09:04:59

CTKB institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	104,267	USD 370,148
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	17,215	USD 61,113
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	164,969	USD 585,640
Total =		286,451	USD 1,016,901

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer